Source: Siyu MedTech; Editor: Qi Yuan
Reprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
BrosMed MedicalBrosMed Medical, an industry-leading enterprise focused on the development and application of technologies and products for interventional treatment of complex vascular diseases,RecentlyAnnounced on [Date]Mr. Scott J. AddonizioOfficially joined and served asGlobal Chief Operating Officer (COO) of the Group。
Mr. Scott J. Addonizio has accumulated nearly 30 years of professional knowledge and extensive experience in the medical device industry.Formerly served as Senior Vice President of Cordis and Chief Operating Officer of MedAllianceDuring his tenure at MedAlliance, he leveraged his exceptional fundraising capabilities to secure crucial funding for the company's continued growth. Prior to MedAlliance's successful acquisition by Cordis in October 2023,He is fully responsible for the company's global operations, effectively driving business expansion and achieving strong double-digit growth.。In addition, Mr. Addonizio has also served asBoard Member and Chief Operating Officer of OrbusNeich Medical, overseeing all aspects of the company's global operations, including key areas such as sales and marketing. Under his leadership, OrbusNeich's global revenue had grown significantly before he returned to the United States in 2019.Has reached a scale of approximately 100 million US dollarsMr. Addonizio currently holds several key positions in various organizations, includingBoard Member of Simpson Intervention and Partner at Cultivation Capital。Mr. Addonizio stated"I am very honored to join BrosMed and work again with my good friend, Mr. Li Bin. I have lived and worked in China for 15 years, and in the past 5 years, I returned to the United States. Now is the best time for us to jointly open a new chapter in the global market.BrosMed Medical has already occupied an important position in the global vascular intervention market, and I am very excited that the company can further expand its international influence through continuous innovation.”BrosMed Medical Chairman and CEO Mr. Li Bin said"Scott and I have known each other for 23 years, and we have also worked closely together for 7 years. Scott is a person with a strong sense of responsibility, positivity, and dedication. I have learned a lot from him. At the same time, Scott and I share a love for basketball, and we often lead teams in competitive events, experiencing the essence of cooperation and competition in tense matches," Mr. Li Bin added: "Today, I am very pleased to announce that we are fortunate to have invited Scott to join BrosMed Medical, our growing team. Scott and I have walked an extraordinary journey together before, and after 12 years, we will once again collaborate."BrosMed Medical is a team that focuses on technology, creativity, and ambition. We believe that Scott's joining as the Global Chief Operating Officer will further enhance BrosMed Medical's ability to serve clients and patients worldwide and create more value for our partners.。”BrosMed Medical focuses on the research, development, production, and global sales of interventional diagnosis and treatment technologies and products for complex vascular diseases. It is an industry-leading multinational group specializing in vascular interventional medical devices. BrosMed Medical consistently adheres to independent research and innovation.Globally ownedMore than 20 product series and over 500 product registration certificates, covering multiple fields such as cardiovascular intervention, peripheral vascular intervention, vascular access, neurointervention, and interventional accessories.Marketed in more than 100 countries and regions worldwide。BrosMed Medical, with the mission of "Embracing Life through Technology," actively practices"Empower Chinese Innovation, Benefit Global Patients"The concept is dedicated to continuously providing safe, effective, high-quality, and innovative vascular interventional solutions for doctors, experts, and patients worldwide.
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
